生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Everolimus is an inhibitor of mTOR through binding FKBP12 with IC50 of 1.6-2.4 nM, which also shows inhibition in several hormone therapy–sensitive ERb breast cancer xenograft models like MCF7 and HCC1500, as well as three patient-derived primary explant models BR0555, CTC174, and HBCx3. Up to now, AZD2014 enters Phase 1 trial in solid tumours. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
CAKI1 | Cytotoxic Assay | 72 h | IC50=14 μM | 24445311 | |
Colo205 | Cytotoxic Assay | 72 h | IC50=20 μM | 24445311 | |
Colo205 | Function Assay | 24 h | Inhibits mTORC1 in human COLO205 cells assessed as reduction of S6 phosphorylation at 0.1 to 8 uM | 24836070 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.04mL 0.21mL 0.10mL |
5.22mL 1.04mL 0.52mL |
10.44mL 2.09mL 1.04mL |